- Home
- TCBP
as 12-18-2024 1:42pm EST
TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled the company to develop a range of clinical-stage cell therapies designed to combat cancer and viral infection.
| Founded: | 2013 | Country: | United Kingdom |
| Employees: | N/A | City: | HOLYTOWN |
| Market Cap: | 3.0M | IPO Year: | 2022 |
| Target Price: | $3.00 | AVG Volume (30 days): | 378.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -78.81 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.44 - $41.50 | Next Earning Date: | 02-09-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest TC BioPharm (Holdings) plc News
TCBP Breaking Stock News: Dive into TCBP Ticker-Specific Updates for Smart Investing
PR Newswire
6 hours ago
TCBP Announces General Meeting of Shareholders to Approve One-Time Shareholder Dividend
Benzinga
6 hours ago
EXCLUSIVE: Penny Stock TC BioPharm Proposes Special Stock Dividend
MT Newswires
7 days ago
CareDx, TC BioPharm Collaborate to Use AlloCell Test for Achieve Trial
PR Newswire
7 days ago
TCBP Partners with CareDx to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy
PR Newswire
14 days ago
TCBP Provides Quarterly Update on the ACHIEVE (UK) Clinical Trial
MT Newswires
19 days ago
Sector Update: Health Care Stocks Advance Pre-Bell Friday
MT Newswires
21 days ago
TC BioPharm Files $100 Million Mixed Shelf Offering
PR Newswire
a month ago
TCBP Awarded Non-Dilutive Funding, ScaleReady's G-Rex® Grant
Compare TCBP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TCBP TC BioPharm (Holdings) plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.